
Century Therapeutics Launches with $250 Million for Induced Pluripotent Stem Cell Platform
Century’s iPSCs, which are stem cells that can be generated from adult stem cells, have unlimited self-renewing capacity, the company said, which enables multiple rounds of cellular engineering.